The ‘mutational landscape’ of intrahepatic cholangiocarcinoma, a rare, highly fatal form of liver cancer that disproportionately affects people in Asian countries, has been identified by an international team of researchers. The findings could potentially lead to earlier and more accurate diagnosis and increased survival rates for patients with the disease, also known as intrahepatic bile duct cancer.

Related Links:

Publication date: Available online 9 August 2018Source: IDCasesAuthor(s): Mohamed Eisa, Kibrewessen Tefera, Anahita AlvanpourAbstractWe are presenting a case of Listeria monocytogenes spontaneous bacterial peritonitis (SBP) monomicrobial non-neutrocytic bacterascites (MNS) in a patient with malignant ascites secondary to cholangiocarcinoma who underwent peritoneal catheter placement. Listeria peritonitis is uncommon, with cancer patients at a higher risk. Listeria infection should be suspected in susceptible patients once there is no response to empiric antibacterial or if the initial culture report shows gram positive bac…

Source: IDCasesCategory: Infectious Diseases Source Type: research

This study was performed to evaluate the cytotoxic effects of asiatic acid on two human CCA cell lines (KKU-156 and KKU-213). Cell viability was determined by a sulforhodamine B (SRB) assay. Morphological changes of the cells were observed by microscopy. Cell apoptosis was detected by flow cytometry using annexin V and propidium iodide (PI) staining. Messenger RNA (mRNA) expression levels of BAX, BCL2 and Survivin/BIRC5 were analyzed by real-time polymerase chain reaction (PCR). It was found that asiatic acid efficiently suppressed CCA cellular viability via induction of apoptosis. In addition, the occurrence of asiatic ac…

CONCLUSION: The incidence rate of CCA has decreased since 2002, representing a real decline in the risk of CCA. The incidence of CCA is projected to stabilize by 2025. The survival of patients with CCA remains poor.
PMID: 30078813 [PubMed – as supplied by publisher]

Conditions:   Cholangiocarcinoma;   Biliary Tract Cancer;   HER-2 Protein Overexpression;   HER-2 Gene Amplification Intervention:   Drug: Trastuzumab Sponsor:   Changhoon Yoo Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

ConclusionsRLS can be performed for primary hepatobiliary malignancies with long-term oncologic outcomes comparable to published open and laparoscopic data.

Abstract
Circulating tumor cells (CTC) enter the blood from many carcinomas and represent a likely source of metastatic dissemination. In contrast to the peripheral circulation, KRAS mutation- positive CTC thrive in the portal venous blood of patients with pancreatic ductal adenocarcinoma (PDAC). To analyze the essential interactions that contribute to carcinoma CTC growth and immune resistance, portal venous blood was collected during pancreatico-duodenectomy in 41 patients with peri-ampullary pathologies (PDAC = 11; ampullary adenocarcinoma (AA) = 15; distal cholangiocarcinoma (CC) =&nbs…

Source: Cancer Biology and TherapyCategory: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research

Conclusions: Although FDG-PET may be useful for assessing tumor
progression factors, such as lymph node metastasis, it cannot accurately detect precancerous lesions, such as BilIN
and IPNB without invasive carcinoma.
PMID: 30049183 [PubMed – in process]

Authors: Kaewpitoon N, Kaewpitoon SJ, Meererksom T, Chan-Aran S, Sangwalee W, Kujapun J, Norkaew J, Chuatanam J, Ponpimai S, Pothipim M, Padchasuwan N, Tongtawee T, Matrakool L, Panpimanmas S, Loyd RA, Wakkhuwatthapong P
Abstract
The carcinogenic liver fluke, Opisthorchis viverrini, is a serious health problem in Southeast Asia where infection
is associated with cholangiocarcinoma, a major cause of death in Thailand. This cross-sectional study aimed to screen
for O. viverrini infection among a Thai rural population of 560 individuals from Nakhon Ratchasima, Khonkaen, and
Chaiyaphum provinces with a verbal screening…

Cancer Medicine, EarlyView.

Source: Cancer MedicineCategory: Cancer & Oncology Authors:

AbstractData on the effectivness of PIPAC in patients with peritoneal metastases of pancreaticobiliary origin is scarce. We here present further proof of treatment efficacy in this subset of patients. Repetitive PIPAC treatment with low-dose cisplatin 7.5  mg/m2 and doxorubicin 1.5  mg/m2 body surface area every 6 weeks and prospective data collection. Documentation included microscopic histological regression, median overall survival and treatment-related adverse events. Twelve patients with a median age of 57  years (range 43–78 years) were included. Six patients suffered from pertioneal metasta…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image